Dr. Christian Marsolais reports

THERATECHNOLOGIES INITIATES INCREASED DOSE LEVEL IN PHASE 1 CLINICAL TRIAL OF SUDOCETAXEL ZENDUSORTIDE IN ADVANCED OVARIAN CANCER

Theratechnologies Inc. has moved to the next dose level in part 3 of its phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer. The study's medical review committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol. Study centres are now actively recruiting patients for the second cohort, with one patient already enrolled and treated with the higher dose.

"We are encouraged by the safety and tolerability of the sudocetaxel zendusortide regimen in the first cohort of six patients in part 3 of the phase 1 trial," said trial investigator Dr. Ira Winer, MD, PhD, FACOG, a member of the gynecologic oncology and phase 1 clinical trials multidisciplinary teams at Karmanos Cancer Center and associate professor of oncology at Wayne State University. "We will continue to enroll and monitor patients as we further investigate this novel peptide-drug conjugate in individuals with advanced, platinum-resistant ovarian cancer, a population with high unmet medical need."

Part 3 of the phase 1 study is intended to assess the optimal dose and schedule of sudocetaxel zendusortide, which is being administered on three consecutive weeks followed by one week of rest on days 1, 8 and 15 of each 28-day cycle. The dose for the initial six patients was 1.75 milligrams per kilogram per dose and the dose for the next cohort of patients is 2.50 milligrams per kilogram per dose. The MRC approved initiation of the second cohort following attainment of the threshold of one or less dose-limiting toxicities (DLTs) in the first cohort. The study's updated protocol defines DLTs as any Grade 3 or greater toxicity within the first cycle and any worsening of peripheral neuropathy to Grade 3 or Grade 4 within a three-month period.

"Initiation of treatment at the next dose level is an important milestone for part 3 of the phase 1 study and will allow us to further characterize sudocetaxel zendusortide as a potentially viable therapy for individuals with advanced ovarian cancer," commented Dr. Christian Marsolais, PhD, senior vice-president and chief medical officer at Theratechnologies. "We welcome discussions with potential partners interested in helping to advance development of this novel peptide-drug conjugate."

Theratechnologies completed enrolment of the first cohort of six patients in part 3 of the phase 1 trial in February, 2024, and dosed the first patient in October, 2023. The FDA approved the amended trial protocol in June, 2023.

About sudocetaxel zendusortide (TH1902) and SORT1+ technology

Sudocetaxel zendusortide is a first-of-its-kind sortilin-receptor-targeting (SORT1) peptide-drug conjugate and the first compound to emerge from the company's broader licensed oncology platform. A new chemical entity, sudocetaxel zendusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted fast-track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumours that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a phase 1 clinical trial.

Theratechnologies has established the SORT1+ technology platform as an engine for the development of PDCs ( peptide-drug conjugates) that target SORT1, which is expressed in multiple tumour types. SORT1 is a scavenger receptor that plays a significant role in protein internalization, sorting and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that SORT1 is expressed in 40 per cent to 90 per cent of endometrial, ovarian, colorectal, triple-negative breast (TNBC) and pancreatic cancers, making this receptor an attractive target for anti-cancer drug development.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.